MMSI: Confident in growth and margin targets through 2026, with Wrapsody launch driving portfolio momentum

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at medical devices & supplies - cardiology, neurology, vascular stocks, starting with ICU Medical .

The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs.

The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a very strong Q3. As a group, revenues beat analysts’ consensus estimates by 3.5%.

Luckily, medical devices & supplies - cardiology, neurology, vascular stocks have performed well with share prices up 12.4% on average since the latest earnings results.

Best Q3: ICU Medical

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

ICU Medical reported revenues of $533.3 million, down 9.5% year on year. This print exceeded analysts’ expectations by 4.1%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “We are pleased with our third quarter results."

ICU Medical delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 15% since reporting and currently trades at $149.14.

Is now the time to buy ICU Medical? Access our full analysis of the earnings results here, it’s free for active Edge members.

Penumbra

Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions.

Penumbra reported revenues of $354.7 million, up 17.8% year on year, outperforming analysts’ expectations by 4.2%. The business had an exceptional quarter with an impressive beat of analysts’ constant currency revenue estimates and a solid beat of analysts’ revenue estimates.

Penumbra achieved the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 31.2% since reporting. It currently trades at $295.96.

Is now the time to buy Penumbra? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Artivion

Formerly known as CryoLife until its 2022 rebranding, Artivion develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Artivion reported revenues of $113.4 million, up 18.4% year on year, exceeding analysts’ expectations by 2.6%. It may have had the worst quarter among its peers, but its results were still good as it also locked in an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

Artivion delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 2% since the results and currently trades at $46.53.

Read our full analysis of Artivion’s results here.

Merit Medical Systems

Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy.

Merit Medical Systems reported revenues of $384.2 million, up 13% year on year. This print topped analysts’ expectations by 3.2%. Overall, it was a very strong quarter as it also recorded a solid beat of analysts’ organic revenue estimates and an impressive beat of analysts’ revenue estimates.

Merit Medical Systems had the weakest full-year guidance update among its peers. The stock is up 5.3% since reporting and currently trades at $87.41.

Read our full, actionable report on Merit Medical Systems here, it’s free for active Edge members.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at medical devices & supplies - cardiology, neurology, vascular stocks, starting with Artivion .

The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs.

The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a very strong Q3. As a group, revenues beat analysts’ consensus estimates by 3.5%.

Luckily, medical devices & supplies - cardiology, neurology, vascular stocks have performed well with share prices up 13.5% on average since the latest earnings results.

Weakest Q3: Artivion

Formerly known as CryoLife until its 2022 rebranding, Artivion develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Artivion reported revenues of $113.4 million, up 18.4% year on year. This print exceeded analysts’ expectations by 2.6%. Overall, it was a strong quarter for the company with a solid beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

"Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth. Revenue growth was driven by year-over-year growth in stent grafts of 38%, On-X of 25%, preservation services of 5%, BioGlue of 2%, all compared to the third quarter of 2024. On a constant currency basis, year-over-year stent grafts, On-X, preservation services, and BioGlue grew 31%, 23%, 5%, and 1%, respectively." said Pat Mackin, Chairman, President, and Chief Executive Officer.

Artivion scored the fastest revenue growth and highest full-year guidance raise, but had the weakest performance against analyst estimates of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 1.4% since reporting and currently trades at $46.82.

Is now the time to buy Artivion? Access our full analysis of the earnings results here, it’s free for active Edge members.

Best Q3: ICU Medical

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

ICU Medical reported revenues of $533.3 million, down 9.5% year on year, outperforming analysts’ expectations by 4.1%. The business had a stunning quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

The market seems happy with the results as the stock is up 17.4% since reporting. It currently trades at $152.18.

Is now the time to buy ICU Medical? Access our full analysis of the earnings results here, it’s free for active Edge members.

Merit Medical Systems

Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy.

Merit Medical Systems reported revenues of $384.2 million, up 13% year on year, exceeding analysts’ expectations by 3.2%. It may have had the worst quarter among its peers, but its results were still good as it also locked in an impressive beat of analysts’ organic revenue estimates and a solid beat of analysts’ revenue estimates.

Merit Medical Systems delivered the weakest full-year guidance update in the group. Interestingly, the stock is up 5.5% since the results and currently trades at $87.65.

Read our full analysis of Merit Medical Systems’s results here.

Penumbra

Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions.

Penumbra reported revenues of $354.7 million, up 17.8% year on year. This result beat analysts’ expectations by 4.2%. It was an exceptional quarter as it also produced an impressive beat of analysts’ constant currency revenue estimates and a solid beat of analysts’ revenue estimates.

Penumbra pulled off the biggest analyst estimates beat among its peers. The stock is up 32.6% since reporting and currently trades at $299.

Read our full, actionable report on Penumbra here, it’s free for active Edge members.

Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra and its peers.

The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs.

The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a very strong Q3. As a group, revenues beat analysts’ consensus estimates by 3.5%.

Luckily, medical devices & supplies - cardiology, neurology, vascular stocks have performed well with share prices up 13.5% on average since the latest earnings results.

Penumbra

Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions.

Penumbra reported revenues of $354.7 million, up 17.8% year on year. This print exceeded analysts’ expectations by 4.2%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ constant currency revenue estimates and a solid beat of analysts’ revenue estimates.

Penumbra pulled off the biggest analyst estimates beat of the whole group. Unsurprisingly, the stock is up 32.6% since reporting and currently trades at $299.

Is now the time to buy Penumbra? Access our full analysis of the earnings results here, it’s free for active Edge members.

Best Q3: ICU Medical

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

ICU Medical reported revenues of $533.3 million, down 9.5% year on year, outperforming analysts’ expectations by 4.1%. The business had a stunning quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

The market seems happy with the results as the stock is up 17.4% since reporting. It currently trades at $152.18.

Is now the time to buy ICU Medical? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Artivion

Formerly known as CryoLife until its 2022 rebranding, Artivion develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Artivion reported revenues of $113.4 million, up 18.4% year on year, exceeding analysts’ expectations by 2.6%. It may have had the worst quarter among its peers, but its results were still good as it also locked in an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

Artivion delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 1.4% since the results and currently trades at $46.82.

Read our full analysis of Artivion’s results here.

Merit Medical Systems

Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy.

Merit Medical Systems reported revenues of $384.2 million, up 13% year on year. This number topped analysts’ expectations by 3.2%. It was a very strong quarter as it also recorded a solid beat of analysts’ organic revenue estimates and an impressive beat of analysts’ revenue estimates.

Merit Medical Systems had the weakest full-year guidance update among its peers. The stock is up 5.5% since reporting and currently trades at $87.65.

Read our full, actionable report on Merit Medical Systems here, it’s free for active Edge members.

What Happened?

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Medical Devices & Supplies - Cardiology, Neurology, Vascular company Merit Medical Systems jumped 4%. Is now the time to buy Merit Medical Systems? Access our full analysis report here, it’s free for active Edge members.
• Medical Devices & Supplies - Specialty company Globus Medical jumped 4.2%. Is now the time to buy Globus Medical? Access our full analysis report here, it’s free for active Edge members.
• Hospital Chains company Tenet Healthcare jumped 3.6%. Is now the time to buy Tenet Healthcare? Access our full analysis report here, it’s free for active Edge members.
• Health Insurance Providers company Progyny jumped 4.2%. Is now the time to buy Progyny? Access our full analysis report here, it’s free for active Edge members.
• Drug Development Inputs & Services company IQVIA jumped 3.5%. Is now the time to buy IQVIA? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Globus Medical (GMED)

Globus Medical’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 14 days ago when the stock gained 32.7% on the news that the company reported third-quarter results that significantly beat analyst estimates and raised its full-year guidance. For the third quarter, net sales reached $769 million, a 22.9% increase year-on-year that surpassed the $734.8 million consensus estimate. The company's adjusted earnings per share (EPS) was even more impressive, coming in at $1.18, which was substantially higher than the projected $0.77. Buoyed by the strong performance, Globus Medical increased its full-year 2025 guidance for both revenue and adjusted EPS. Overall, the significant top- and bottom-line beats, coupled with a more optimistic outlook for the full year, drove investor enthusiasm.

Globus Medical is up 5% since the beginning of the year, and at $85.95 per share, it is trading close to its 52-week high of $93.32 from January 2025. Investors who bought $1,000 worth of Globus Medical’s shares 5 years ago would now be looking at an investment worth $1,470.